← All Mainz Biomed NV filings

Mainz Biomed NV 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

MYNZ
Mainz Biomed NV
20-F: Mainz Biomed N.V. Reports Annual Results for Fiscal Year 2024, Focuses on ColoAlert Expansion and U.S. Market Entry
Mainz Biomed N.V. announces its annual results for the fiscal year ended December 31, 2024, highlighting a strategic shift towards European market expansion and preparations for U.S. market entry.
MYNZ
Mainz Biomed NV
20-F: Mainz Biomed N.V. Files Form 20-F, Details ColoAlert Expansion and U.S. Market Entry Strategy
Mainz Biomed N.V. files its annual report on Form 20-F, outlining its business strategy, financial performance, and risk factors, with a focus on expanding its ColoAlert product in Europe and entering the U.S. market.